Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Entero Healthcare Solutions share price today

ENTEROPharmacyConsolidatedPrices to 18 Nov 2026Results to Sep 2026

10Y not available: listed Feb 2024
Price, 200-day average and NIFTY 500Since Feb 2024Since Feb 2024

The price is 39.1% above its 200-day average and 55 points ahead of the NIFTY 500 since listing in Feb 2024

18 Nov 2026₹1,986.00Since listing in Feb 2024: Entero Healthcare Solutions +72.8%, NIFTY 500 +18.1%
₹1,000₹2,000Nov 24Nov 25Nov 26

Price growth

1Y3Y5Y10Y1Y+87.0%3YToo short5YToo short10YToo short

EPS and P/ESince Feb 2024Since Feb 2024

EPS ₹32.03, up 26% in a year; P/E 62.0

18 Nov 2026₹32.03 EPS
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹40

EPS growth

1Y3Y5Y10Y1Y+26.1%3YNot meaningful5YToo short10YToo short

Revenue and marginsSince Feb 2024Insufficient history, from Mar 2020

Revenue up on a year for 14 quarters in a row; operating margin 5.3%, the highest on this chart

Sep 2026 quarter₹2,087 crore+32.8% on ₹1,571 crore a year earlier · NPM 2.9%
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹2,500

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+34.7%3Y+28.4%/yr5Y+30.0%/yr to Mar10YToo short
OPM average3Y4.0%5Y3.0% to Mar
NPM average3Y2.2%5Y1.2% to Mar

Return on capitalSince Feb 2024Insufficient history, from Mar 2021

ROCE was 13.0% for the four quarters to Sep 2026, up from 1.1% in the year to Mar 2022

Four quarters to Sep 202613.0% ROCE
5%10%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y13.0%3Y8.7% to Mar5Y6.4% to Mar10YToo short

Profit and cashSince Feb 2024Insufficient history, from Mar 2020

Cash from operations was -39% of profit over five years, 66% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹96 crore operating cashProfit ₹146 crore · Free cash ₹29 crore
FY22
FY23
FY24
FY25
FY26
₹200−₹100

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+51.2%3Y+159.4%/yr5YNot meaningful10YToo short

ReinvestmentSince Feb 2024Insufficient history, from Mar 2020

Capex was ₹68 crore in the year to Mar 2026, 1.6 times depreciation

FY26₹68 crore capexWork in progress ₹2 crore
FY22
FY23
FY24
FY25
FY26
0₹75

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+497.0% to Mar3Y+130.4%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Dec 2022Insufficient history, from Dec 2022

Debt ÷ equity 0.51 at 30 Sep 2026; profit covered interest 4.2x over the last four quarters

Sep 2026 balance sheet0.51 debt ÷ equityNet debt ₹674 crore
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
06x

Safety

Now3Y ago
Debt ÷ equity0.513Y ago0.83
Int. cover4.2x3Y ago1.3x

Operating healthSince Feb 2024Since Feb 2024

Working capital fell from 54 to 35 days in 5 years

Year to Mar 202635 days working capital
4060Mar 22Mar 24Mar 26
Working cap.351Y−303Y+35Y−19
Debtor671Y+83Y+105Y+17
Inventory521Y03Y+115Y−2

OwnershipInsufficient history, from Mar 2024Insufficient history, from Mar 2024

FIIs own 5.76%, down 8.92 points in a year. Promoters hold 52.40%

Share of the company held, %, by quarter end

Sep 2026 quarter5.76% FIIs
20%40%Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y−8.923YToo short
Promoters1Y−0.023YToo short

Entero Healthcare Solutions Ltd · ENTERO · Pharmacy Distribution · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 5 November 2026

Entero Healthcare Solutions share price today: ₹1,986.00 at the close on 18 November 2026, up 87.0% in a year. Entero Healthcare Solutions (ENTERO) is worth ₹8,651 crore, trades at a P/E of 62.0 and has closed between ₹952.50 and ₹2,025.40 over the past 52 weeks. Latest change: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).

MixedBusiness trend from fewer quarters than usual
₹1,986.00Price +87.0% in a year
62.0×P/E higher than 67% of the last 2.5 years
₹2,087 CrRevenue (Sep 2026) +32.8% on a year ago
₹61.0 CrProfit (Sep 2026) +64.9% on a year ago
5.3%Operating margin +1.4 points on a year ago
13.0%ROCE four quarters to Sep 2026
−6%Profit that came in as cash last 3 years

Entero Healthcare Solutions Ltd's share price has risen faster than its earnings: +87.0% in a year, against +26.1% for earnings per share.

The main question: profits are rising, but only −6% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

The price has been rising for 28 weeks, and the P/E is higher than 67% of its own last 2.5 years. Over the last four quarters, results have been improving, with profit +64.9% on a year earlier, and −6% of the last 3 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.

Left out of this page: Its two data sources disagree by up to 37% on reported income across 16 comparable periods, so nothing from the second source is shown here. That is why the PEG ratio and its quarterly curve, the yearly return-on-capital-used (ROIC) line, the total-debt and debt-to-equity series and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Entero Healthcare Solutions share price today?

Entero Healthcare Solutions Ltd's share price was ₹1,986.00 at the close on 18 November 2026. It has been rising for 28 weeks. That is 39.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹953 and ₹2,025, and at that close it sat 96% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Entero Healthcare Solutions Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 20 weeks in a row.

Week by week since 2024: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 77 of 140 weeks

Week by week since 2024: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
16 Feb 2024no NIFTY 500 reading
23 Feb 2024no NIFTY 500 reading
2 Mar 2024no NIFTY 500 reading
7 Mar 2024no NIFTY 500 reading
15 Mar 2024no NIFTY 500 reading
22 Mar 2024no NIFTY 500 reading
28 Mar 2024no NIFTY 500 reading
5 Apr 2024no NIFTY 500 reading
12 Apr 2024no NIFTY 500 reading
19 Apr 2024no NIFTY 500 reading
26 Apr 2024no NIFTY 500 reading
3 May 2024no NIFTY 500 reading
10 May 2024no NIFTY 500 reading
18 May 2024−12.7%
24 May 2024−18.3%
31 May 2024−3.6%
7 Jun 2024−11.9%
14 Jun 2024−9.9%
21 Jun 2024−6.3%
28 Jun 2024−6.0%
5 Jul 2024+1.2%
12 Jul 2024−13.3%
19 Jul 2024−13.6%
26 Jul 2024−7.4%
2 Aug 2024+2.6%
9 Aug 2024+5.5%
16 Aug 2024+8.0%
23 Aug 2024+17.0%
30 Aug 2024+20.6%
6 Sep 2024+27.4%
13 Sep 2024+31.7%
20 Sep 2024+22.5%
27 Sep 2024+29.4%
4 Oct 2024+16.1%
11 Oct 2024+11.4%
18 Oct 2024+22.3%
25 Oct 2024+16.1%
1 Nov 2024+16.6%
8 Nov 2024+23.4%
14 Nov 2024+16.3%
22 Nov 2024+6.2%
29 Nov 2024+3.3%
6 Dec 2024+4.8%
13 Dec 2024+4.6%
20 Dec 2024+11.9%
27 Dec 2024+7.7%
3 Jan 2025+8.4%
10 Jan 2025+15.9%
17 Jan 2025+0.7%
24 Jan 2025+1.7%
1 Feb 2025+1.5%
7 Feb 2025−0.4%
14 Feb 2025−4.9%
21 Feb 2025+7.9%
28 Feb 2025+5.9%
7 Mar 2025+0.6%
13 Mar 2025−6.2%
21 Mar 2025−13.2%
28 Mar 2025−15.4%
4 Apr 2025−6.8%
11 Apr 2025−12.9%
17 Apr 2025+1.5%
25 Apr 2025−1.2%
2 May 2025−8.1%
9 May 2025−5.2%
16 May 2025+9.4%
23 May 2025−1.6%
30 May 2025−19.8%
6 Jun 2025−19.0%
13 Jun 2025−11.9%
20 Jun 2025−12.7%
27 Jun 2025−11.2%
4 Jul 2025−9.7%
11 Jul 2025−2.6%
18 Jul 2025−17.5%
25 Jul 2025−13.3%
1 Aug 2025−1.9%
8 Aug 2025−8.7%
14 Aug 2025−17.6%
22 Aug 2025−14.8%
29 Aug 2025−0.1%
5 Sep 2025+0.5%
12 Sep 2025−4.5%
19 Sep 2025−0.9%
26 Sep 2025−0.4%
3 Oct 2025−9.1%
10 Oct 2025−11.9%
17 Oct 2025−7.5%
24 Oct 2025−13.6%
31 Oct 2025−19.8%
7 Nov 2025−20.3%
14 Nov 2025−12.2%
21 Nov 2025−17.1%
28 Nov 2025−16.6%
5 Dec 2025−18.5%
12 Dec 2025−16.0%
19 Dec 2025−15.4%
26 Dec 2025−16.8%
2 Jan 2026−1.8%
9 Jan 2026+4.0%
16 Jan 2026+8.2%
23 Jan 2026+10.7%
1 Feb 2026+7.1%
6 Feb 2026+5.1%
13 Feb 2026+4.6%
20 Feb 2026+3.3%
27 Feb 2026+0.3%
6 Mar 2026+6.9%
13 Mar 2026+11.5%
20 Mar 2026+26.1%
27 Mar 2026+41.6%
2 Apr 2026+24.3%
10 Apr 2026+6.7%
17 Apr 2026+9.8%
24 Apr 2026+8.5%
30 Apr 2026+7.1%
8 May 2026+8.7%
15 May 2026+7.2%
22 May 2026+28.7%
29 May 2026+18.1%
4 Jun 2026+9.0%
5 Jun 2026+4.9%
9 Jun 2026−3.6%
10 Jun 2026−15.8%
12 Jun 2026−16.9%
17 Jun 2026−10.9%
19 Jun 2026−16.0%
24 Jun 2026−9.4%
25 Jun 2026−4.9%
1 Jul 2026−3.7%
3 Jul 2026−1.7%
10 Jul 2026−13.7%
17 Jul 2026−4.8%
24 Jul 2026+5.9%
31 Jul 2026+7.3%
7 Aug 2026+3.4%
14 Aug 2026+20.4%
21 Aug 2026+21.1%
28 Aug 2026+61.4%
4 Sep 2026+67.3%
11 Sep 2026+57.1%
18 Sep 2026+47.9%
25 Sep 2026+56.2%
28 Sep 2026+49.8%
1 Oct 2026+45.2%
9 Oct 2026+49.1%
16 Oct 2026+31.7%
23 Oct 2026+26.7%
30 Oct 2026+34.4%
6 Nov 2026+34.7%
8 Nov 2026+42.6%
13 Nov 2026+8.0%
18 Nov 2026+6.6%
Each bar is one week, from 2024 to now (140 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 2.8 years the share price moved +73% while the NIFTY 500 moved +18%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Entero Healthcare Solutions this quarter?

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 10 quarters in a row and highest quarterly profit in 16 quarters.

  1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

    In the September 2026 quarter revenue was ₹2,087 crore, +32.8% on a year earlier.

  2. Profit up on a year earlier for 10 quarters in a row

    In the September 2026 quarter profit was ₹61 crore, +64.9% on a year earlier.

  3. Highest quarterly profit in 16 quarters

    Profit of ₹61 crore in the September 2026 quarter is the highest of the last 16 quarters.

What are Entero Healthcare Solutions' latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Entero Healthcare Solutions reported revenue of ₹2,087 crore, up 32.8% from ₹1,571 crore a year earlier, and a profit of ₹61.0 crore, up 64.9% from ₹37.0 crore.

Entero Healthcare Solutions results: July to September 2026 against a year earlier

Entero Healthcare Solutions results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹2,087 crore₹1,571 crore+32.8%
Profit₹61.0 crore₹37.0 crore+64.9%
Earnings per share₹10.46₹7.26+44.1%
Operating margin5.3%3.9%+1.4 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Entero Healthcare Solutions' management discussed these results on a call held on 5 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Entero Healthcare Solutions share price history?

Entero Healthcare Solutions closed at ₹1,986.00 on 18 November 2026, up 87.0% from ₹1,062.10 a year earlier (21 November 2025). Its highest weekly close since February 2024 was ₹2,025.40 on 8 November 2026.

Entero Healthcare Solutions share price: then and now

Entero Healthcare Solutions share price: then and now
WhenCloseChange to 18 Nov 2026
1 week ago · 11 Nov 2026₹2,004.50−0.9%
1 month ago · 19 Oct 2026₹1,503.90+32.1%
6 months ago · 15 May 2026₹1,192.30+66.6%
1 year ago · 21 Nov 2025₹1,062.10+87.0%
Earliest weekly close in our records · 16 Feb 2024₹1,149.55+72.8%
Highest weekly close since February 2024, also the 52-week high · 8 Nov 2026₹2,025.40−1.9%
Lowest weekly close since February 2024, also the 52-week low · 26 Dec 2025₹952.50+108.5%

Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

153 weekly closes from 16 February 2024 to 18 November 2026.

What is the latest news on Entero Healthcare Solutions?

18 Nov 2026: Entero Healthcare Solutions closed at ₹1,986.00, down 0.9% on the week and up 32.1% on the month. 5 Nov 2026: Entero Healthcare Solutions held its results call for July to September 2026. Management guided: FY27 consolidated revenue growth approximately 23% excluding new acquisitions with better delivery expected.

Earlier

  • Results for July to September 2026: Revenue up 32.8% and profit up 64.9% on a year earlier.

What dividend does Entero Healthcare Solutions pay?

Entero Healthcare Solutions has paid no dividend on the exchange since its first close in our records (16 February 2024), the start of the period we checked.

No. Entero Healthcare Solutions Ltd paid out 0% of its profit as dividends in each of its last 7 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 18 November 2026.

What did Entero Healthcare Solutions management say on the latest results call?

On the call for July to September 2026, held on 5 November 2026, Entero Healthcare Solutions' management guided: FY27 consolidated revenue growth approximately 23% excluding new acquisitions with better delivery expected.

“However, you can be rest assured that it would be better than what we had guided before, both on growth and on margin.”Prabhat Agrawal, on the call for July to September 2026

What management guided

  • FY27 operating margin 5% with better delivery expected.
  • FY27 operating profit-to-operating-cash-flow conversion 50% retained.
  • FY27 MedTech revenue above ₹1,000 crore.
  • Calendarisation benefit to taper partly in Q3 and fully in Q4 absent new deals.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 5 November 2026.

What to watch in Entero Healthcare Solutions' next results?

When Entero Healthcare Solutions reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Organic outperformance to persist as calendarisation fades in coming quarters - per ex-deal endeavour commentary.

Management raised each of these on the latest results call.

  • Organic outperformance to persist as calendarisation fades in coming quarters - per ex-deal endeavour commentary.
  • Government collections to stay current with no repeat reallocation drag - per one-off timing explanation.
  • MedTech full-year scale to land above deal-time base with value mix intact - per above-goal signal.

Which stock lists is Entero Healthcare Solutions on?

Entero Healthcare Solutions is on 3 of our India lists: Multibagger study list, Momentum stocks and Pharma stocks.

Is Entero Healthcare Solutions profitable?

Entero Healthcare Solutions Ltd earned ₹61.0 Cr of net profit in the Sep 2026 quarter, +64.9% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹146 Cr. Over 6 years profit has grown 129.5% a year on average. The same quarter a year earlier earned ₹37.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The Sep 2026 quarter's profit is 2.9% of that quarter's revenue.

For the full year, FY26 profit was ₹146 Cr (+36.4% on the year before).

Why profit moved: revenue changed +32.8% on a year earlier and the margin moved +1.4 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +50.1% and revenue +34.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY26-Q4. Operating margin rose; annual revenue requires a reported-versus-comparable distinction

FY27-Q1. Annual framework retained; margin bridge and cash delivery remain the tests

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

How much revenue does Entero Healthcare Solutions make, and is it growing?

Entero Healthcare Solutions Ltd reported ₹2,087 Cr of revenue in the Sep 2026 quarter, +32.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 6 years it has grown 30.2% a year on average. The last full year, FY26, came in at ₹6,591 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹7,644 Cr.

FY26 revenue was ₹6,591 Cr, +29.3% on the year before.

Recent pace: the last four quarters grew +34.8% on average, against 30.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +34.7%, against +31.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +51.2%, against +60.0% a year (rolling over).

FY26-Q4. Operating margin rose; annual revenue requires a reported-versus-comparable distinction

FY27-Q1. Annual framework retained; margin bridge and cash delivery remain the tests

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

How much of every ₹100 of sales does Entero Healthcare Solutions keep?

Entero Healthcare Solutions Ltd's operating margin was 5.3% in the Sep 2026 quarter, 1.4 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 0.8% and 4.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The Value Chain Climb applies because management describes a broader commercial role. Group operating-margin progression is consistent with this mechanism, but the specific MedTech contribution is not quantified. Further contribution depends on existing manufacturer relationships and organic MedTech execution, rather than assuming another acquisition wave. Customer demand, manufacturer economics and competitor responses remain relevant: a broader role creates costs as well as revenue, and the latest call withheld category contribution. This driver includes the related mix and procurement benefits rather than adding them again as separate profit pools.

Why the margin moved: operating margin changed +1.3 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

FY26-Q4. Operating margin rose; annual revenue requires a reported-versus-comparable distinction

FY27-Q1. Annual framework retained; margin bridge and cash delivery remain the tests

Why-sources: our stock research file (10 October 2026) and the company’s own results for those quarters.

Watch next

Metric
Commercial MedTech mix
Threshold
Commercial demand-generation and servicing costs absorb the gross-margin benefit, leaving group operating margins below the retained annual goal.
Which result
the next result

Is Entero Healthcare Solutions' profit turning into cash?

Over the last 3 years Entero Healthcare Solutions Ltd's operations used more cash than they brought in, so cash conversion was −6%, a gap worth watching. In FY26 it brought in ₹96.0 Cr of operating cash against ₹146 Cr of profit. After ₹68.0 Cr of spending on assets, ₹28.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. The annual operating-cash improvement has a measurable working-capital counterpart, and management attributes improvement to inventory, collections and MedTech supplier terms. The latest call says inventory optimization remains incomplete and customer mix controls collection timing. This is a conditional cash-release mechanism, not evidence that growth has become self-funding across a cycle.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −6% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Watch next

Metric
Working-capital execution
Threshold
Supplier terms stop offsetting customer credit and annual operating-cash conversion misses the retained commitment.
Which result
the next result

Where does Entero Healthcare Solutions' cash go?

Entero Healthcare Solutions Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 74 days in FY26, down from 82 days in FY21. It spent ₹84.0 Cr on assets over the last 3 years. Customers take 67 days to pay, and stock sits for 52 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹6,591 Cr, each day of that cycle ties up about ₹18.1 Cr, so roughly ₹1,336 Cr is tied up in the business at any time.

FY26: customers took 67 days to pay and stock sat for 52 days, about 1.7 months of sales sitting as stock, for a full cycle of 74 days, shorter than FY21's 82.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 52 days. Customers pay about 67 days after that. Suppliers are paid at 45 days. Together that makes the 74-day cycle.

Spending on assets: ₹84.0 Cr over the last 3 years, against ₹99.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹2.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

What is Entero Healthcare Solutions' P/E ratio, and how does it compare with its own history?

Entero Healthcare Solutions Ltd's P/E is 62.0×, in the middle of its own history: higher than 67% of past readings. Its usual P/E (the middle reading) is 54.9×, over 2.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹32.02.

62.0×P/E · higher than 67% of its last 2.5 years

Why the multiple is where it is: over the past year earnings per share moved +26.1% while the price moved +87.0%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 37% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What growth does the Entero Healthcare Solutions share price assume?

Worked out from its price on 11 October 2026, Entero Healthcare Solutions Ltd's share price assumed profit growth of about 25.5% a year. Over the past 6 years its profit actually grew 129.5% a year. Today its P/E is 62.0×, higher than 67% of its own last 2.5 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Is the Entero Healthcare Solutions business getting better or worse?

Entero Healthcare Solutions Ltd's business is giving mixed signals. Growth has been steadily positive, but ROCE at 13.0% (four quarters to Sep 2026) is below the 15% level needed to call it steady growth. This is based on 9 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highRevenue growth · latest (Sep 2026) +34.7%, range +22.5% to +34.7%
RisingProfit growth · latest (Sep 2026) +51.2%, range +36.1% to +592.9%
Steady highEPS growth · latest (Sep 2026) +26.1%, range −20.5% to +53.0%
RisingROCE · latest (four quarters to Sep 2026) 13.0%, range 5.0% to 13.0%

Why it matters: when the lines disagree, each line above matters more than any single label.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+29.3%+25.9%+30.0%—
Profit+36.4%———
EPS+21.3%———
Share price+87.0%———
+32.8%Revenue growth (Sep 2026) · latest quarter against a year ago
+64.9%Profit growth (Sep 2026) · latest quarter against a year ago
30.2%Revenue, 6 years · yearly growth over the long run

What is the Entero Healthcare Solutions story, and has it been checked?

Entero Healthcare Solutions Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: mid expansion.

NOT YET CHECKED

From the numbers. Operating…

From the price. Price stage 2, week 28, above its 200-day line, relative strength rising.

Where they disagree. The weekly snapshot, curve and normalization use different percentile series, so their ranks are retained separately rather than merged.

What is not proven yet. A subsequent full-year result showing that the promised operating margin was maintained but operating cash flow remained negative would break the thesis that commercial mix and procurement gains are producing economically retained earnings.

The key numbers to watch, and the level that would change the picture

The key numbers to watch, and the level that would change the picture
MeasureNowWhy it mattersWhat to watch
Commercial MedTech mixHIGHDemand generation and servicing can retain more value than fulfillment, provided the extra margin exceeds staffing, equipment…Commercial demand-generation and servicing costs absorb the gross-margin benefit, leaving group operating margins below the retained annual goal.
Retailer wallet-share captureHIGHExisting retailers can consolidate purchasing with Entero as range and service improve.Organic growth falls below the disclosed industry comparator and management identifies lost wallet share rather than temporary timing.
Acquisition calendarization with an…MEDIUMPreviously acquired businesses contribute for a longer period while management focuses on integration.Acquired-business retention deteriorates or management resumes material acquisitions before demonstrating integration and cash delivery.
Working-capital executionMEDIUMInventory optimization and supplier terms can release operating cash as the acquired platform settles.Supplier terms stop offsetting customer credit and annual operating-cash conversion misses the retained commitment.

Everything further down this page is evidence for or against these.

The numbersmid-way through a rise in resultsFY26-Q2 to FY27-Q1
The pricerising, above the 200-day averageFY26-Q2 to FY27-Q1
The whymultiple near its usual level, earnings risingFY26-Q2 to FY27-Q1

FY26-Q2FY27-Q1

What the surface reading misses. The surface reading is: The latest quarterly profit and margin suggest improving execution. The research reads it further: Operating profit growth has to overcome higher interest, while minority participation determines how much consolidated profit reaches listed shareholders.

What the surface reading misses. The surface reading is: The exit quarter improved operating delivery. The research reads it further: Commercial mix and procurement can lift operating profit, but equipment timing changed minority allocation and reported quarter comparisons.

  • 1 · Operating leveragequiet
  • 2 · Value-added mixbuilding
  • 3 · Management changequiet
  • 4 · Paying down debtquiet
  • 5 · Regulatory approvalquiet
  • 6 · Order-book winsquiet
  • 7 · Consolidationquiet
  • 8 · Demerger or value unlockquiet
  • 9 · Buybackquiet
  • 10 · New geographiesquiet
  • 11 · More business from existing customersquiet
  • 12 · New product launchquiet
  • 13 · Mandatory normsquiet
  • 14 · A bigger market to servequiet
  • 15 · Market-share gainsquiet
  • 16 · Asset qualityquiet

Lever 2 · Value-added mix: building. Demand generation and servicing can retain more value than fulfillment, provided the extra margin exceeds staffing, equipment and funding costs. What proves it keeps working: Commercial MedTech mix. It stops working if Commercial demand-generation and servicing costs absorb the gross-margin benefit, leaving group operating margins below the retained annual goal.

Sources: our stock research file (10 October 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

The whole page in one table. Each row links to its section.
SectionWhere it is nowThe one thing to watch next
Margin5%Commercial MedTech mix
Cashsee the sectionWorking-capital execution

Did Entero Healthcare Solutions management deliver what it promised?

What Entero Healthcare Solutions Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

FY27 Acquisition Strategy Reversed · 5 November 2026. In the Aug 2026 call, management said it was not looking for any major acquisition in FY27 and did not expect to do big acquisitions during the year. By the Nov 2026 call, management was evaluating opportunities that could close during the year and was aiming for transactions with at least INR 100 crores of revenue, a material shift in M&A strategy that was not explained.

FY27 Revenue Guidance Is Internally Unreconciled · 10 August 2026. May 2026 set FY27 consolidated revenue growth at 23% excluding new acquisitions. The latest call's prepared remarks instead state approximately 25%, while the Q&A repeats 23%, creating an approximately 9% difference in the growth assumption with no explanation.

Reported Distribution Network Has Contracted Without Reconciliation · 10 August 2026. The latest call reports materially fewer retail customers, hospital customers, SKUs, and districts than both prior calls, despite describing the platform as continuing to scale and reporting more warehouses. Management does not explain whether the definitions changed, whether customers were exited, or why the network metrics declined; this is material because the network is presented as the company's core moat and growth foundation.

GLP-1 Stated Market Share Halved · 26 May 2026. In the Feb 2026 call, management claimed they were capturing almost 10% of the GLP drug market due to their pan-India presence and unique value proposition. However, in the May 2026 call, they stated they are capturing only about 5% of the overall industry value for GLP drugs, halving their claimed market share without explaining the sudden apparent drop.

Every quote above is taken word for word from the company’s own earnings calls.

What is Entero Healthcare Solutions management's track record?

The August transcript describes deliberate low-margin exits and retained guidance; cash funding, comparable customer counts and owner earnings remain unsettled.

Regulatory and governance record

The ACE Cardiopathy GST e-invoice penalty is named, but it is not evidence of management fraud; the earlier temporary licence action remains a compliance caution.

0%Promoter shares pledged

Checked 14 October 2026.

How much does Entero Healthcare Solutions earn on its capital?

Entero Healthcare Solutions Ltd earned a ROCE of 10% in FY26. That is up from a low of 1% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 2.2% net margin and 1.83× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 2.2% net margin × 1.83× asset turnover × 2.13× leverage (assets divided by equity) ≈ 8.6% on equity. The margin does its share; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 37% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Does Entero Healthcare Solutions have too much debt?

Entero Healthcare Solutions Ltd had ₹677 Cr of borrowings against ₹1,689 Cr of equity in FY26, so its debt is 0.40× its equity. Its operating profit is 5 times its interest bill. Over 5 years borrowings went from ₹720 Cr to ₹677 Cr. Over the last 3 of those years it spent ₹84.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 37% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Entero Healthcare Solutions shareholding pattern?

Foreign institutions cut their stake in Entero Healthcare Solutions Ltd by 18.1 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 5.8% of the company. Domestic institutions moved +13.4 points over the same period, to 21.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: −18.1 points over 8 quarters, to 5.8%; Domestic institutions: +13.4 points over 8 quarters, to 21.2%; Promoters: +0.0 points over 8 quarters, to 52.4%.

Why the owners changed: foreign institutions moved −18.1 points and domestic institutions +13.4 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.

How far is Entero Healthcare Solutions from balance-sheet trouble?

For Entero Healthcare Solutions Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Entero Healthcare Solutions rank in its industry?

69.1 out of 100, rank 1 of 5 in Pharmacy Distribution, with 72% of the evidence available.

Entero Healthcare Solutions Ltd scores 69.1 out of 100 against the 5 companies it is compared with in Pharmacy Distribution, ranking 1. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 24.9 + 14.2 + 10 + 20 = 69.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Entero Healthcare Solutions compared with?

Entero Healthcare Solutions ranks 1 of 5 Pharmacy Distribution companies on the 4-Factor Sector Score, with 69.1 out of 100.

  1. 1Entero Healthcare Solutions Ltd this pageENTERO · leader · Most evidence points up · 72% evidence69.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.9/35 · Revenue 34.7% · Profit 51.2% · Operating margin change 1 points · 95% evidenceCapital efficiency 14.2/25 · ROCE 10.5% (year to Mar 2026) · Operating margin 5.3% · 76% evidenceValuation 10.0/20 · P/E 62× · PEG — · 0% evidenceRelative strength 20.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 49.2% · Strength vs NIFTY 500 (same reading) 46.1% · 1 year 87% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.9 + 14.2 + 10 + 20 = 69.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Medplus Health Services LtdMEDPLUS · basing · Evidence leans down · 90% evidence36.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 13.3/35 · Revenue 20.6% · Profit 8.2% · Operating margin change -1 points · 100% evidenceCapital efficiency 18.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 8.3% · 100% evidenceValuation 5.0/20 · P/E 34.1× · PEG 3.85 · 50% evidenceRelative strength 0.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -21.7% · Strength vs NIFTY 500 (same reading) -23.5% · 1 year -21.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 13.3 + 18.1 + 5 + 0 = 36.4 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.
  3. 3Zota Health Care LtdZOTA · turning · Too little evidence to rank firmly · 56% evidence31.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 12.0/35 · Revenue 68.9% · Profit -80% · Operating margin change -3.4 points · 74% evidenceCapital efficiency 1.3/25 · ROCE -8.5% (year to Mar 2026) · Operating margin 1.5% · 100% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 8.1/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -3.7% · 1 year -22% · 25% evidence · 4 of 12 weeks aheadExact sum: 12 + 1.3 + 10 + 8.1 = 31.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  4. 4Health X Platform LtdHEALTHX · quiet · Too little evidence to rank firmly · 49% evidence46.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.9/35 · Revenue 41.6% · Profit -80% · Operating margin change 3.4 points · 71% evidenceCapital efficiency 7.3/25 · ROCE 0% (year to Mar 2026) · Operating margin -4.5% · 76% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -10.8% · 1 year — · 25% evidence · 1 of 12 weeks aheadExact sum: 21.9 + 7.3 + 10 + 7.5 = 46.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  5. 5Sastasundar Ventures LtdSASTASUNDR · Too little evidence to rank firmly · 36% evidence41.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.2/43.75 · Revenue 8.8% · Profit 100% · Operating margin change 5.4 points · 33% evidenceCapital efficiency 8.0/31.25 · ROCE -1.3% (year to Mar 2025) · Operating margin -3% · 71% evidenceValuation 9.3/25 · P/E 33.6× · PEG — · 35% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 24.2 + 8 + 9.3 = 41.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharmacy Distribution, all 5 compared on one page.

Which companies are close to Entero Healthcare Solutions in size?

Entero Healthcare Solutions is the largest of 5 Pharmacy Distribution companies on Sector Alpha by market value (at the 18 November 2026 close). It is the largest. Just below it: Medplus Health Services, Zota Health Care, Health X Platform and Sastasundar Ventures.

Pharmacy Distribution companies close in size

  1. Entero Healthcare Solutions Ltd ₹8,652 crore
  2. Medplus Health Services Ltd ₹7,214 crore
  3. Zota Health Care Ltd ₹4,552 crore
  4. Health X Platform Ltd ₹874 crore
  5. Sastasundar Ventures Ltd ₹874 crore

All 5 Pharmacy Distribution companies, largest first

Companies close in size in other industries

  1. Shiprocket Ltd ₹8,823 crore
  2. Raghav Productivity Enhancers Ltd ₹8,784 crore · Refractories
  3. Entero Healthcare Solutions Ltd ₹8,652 crore
  4. P N Gadgil Jewellers Ltd ₹8,611 crore · Diamond, Gems & Jewellery
  5. Steel Strips Wheels Ltd ₹8,583 crore · Auto Ancillaries - Wheels

What else do people ask about Entero Healthcare Solutions?

What is Entero Healthcare Solutions's share price today?

Entero Healthcare Solutions Ltd's share price is ₹1,986.00, +87.0% over the past year. The whole company is worth ₹8,651 Cr on the market.

In the last 52 weeks it traded between ₹953 to ₹2,025; today it is 96% of the way up from the low, 39.1% above its 200-day average (as of 18 November 2026).

What were Entero Healthcare Solutions's latest quarterly results?

Entero Healthcare Solutions Ltd reported revenue of ₹2,087 Cr and net profit of ₹61.0 Cr for the Sep 2026 quarter. Revenue rose 32.8% and profit rose 64.9% compared with a year earlier. Earnings per share were ₹10.46.

The operating margin was 5.3%, 1.4 percentage points higher than a year earlier (as of 18 November 2026).

What is Entero Healthcare Solutions's market cap?

Entero Healthcare Solutions Ltd's market capitalisation is ₹8,651 Cr at a share price of ₹1,986.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).

How is Entero Healthcare Solutions performing?

Entero Healthcare Solutions Ltd's share price has been rising for 28 weeks. In its latest quarter, revenue rose 32.8% and profit rose 64.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 20 weeks running (as of 18 November 2026).

Will Entero Healthcare Solutions's share price go up?

This page does not forecast Entero Healthcare Solutions Ltd's share price. What it shows instead: the share price is ₹1,986.00, and it has been rising for 28 weeks. Its P/E of 62.0× is higher than 67% of its own last 3 years (as of 18 November 2026).

Who owns Entero Healthcare Solutions?

Promoters own 52.4% of Entero Healthcare Solutions Ltd, foreign institutions 5.8%, domestic institutions 21.2% and the public 20.7% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 18.1 percentage points over 8 quarters (as of 18 November 2026).

Does Entero Healthcare Solutions have too much debt?

Entero Healthcare Solutions Ltd has a moderate amount of debt: its debt is 0.51× its equity, and its operating profit is 4 times its interest bill. At Sep 2026 borrowings were ₹904 Cr against equity of ₹1,782 Cr.

Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026).

Where is Entero Healthcare Solutions in its business cycle?

Entero Healthcare Solutions Ltd's FY26 operating margin was 4.0%, against a 7-year range of 0.8% to 4.0%. The latest quarter was 5.3%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).

What could break the Entero Healthcare Solutions story?

The main question: profits are rising, but only −6% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).

Is Entero Healthcare Solutions a stock worth studying right now?

What the numbers show: Entero Healthcare Solutions Ltd's share price has risen faster than its earnings: +87.0% in a year, against +26.1% for earnings per share. The main open question: whether the cash starts to follow the profit.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).

Is there a Entero Healthcare Solutions share price forecast for 2026?

What management itself guided: FY27 consolidated revenue growth approximately 23% excluding new acquisitions with better delivery expected.

Where does this page get Entero Healthcare Solutions' management information?

From Entero Healthcare Solutions' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.